CLINICAL OUTCOMES FOLLOWING CORONARY STENTING IN JAPANESE PATIENTS WITH AND WITHOUT PROTON PUMP INHIBITOR  by Shimomura, Hideki et al.
A52.E493
JACC March 9, 2010
Volume 55, issue 10A
 HYPERTENSION, LIPIDS AND PREVENTION 
CLINICAL OUTCOMES FOLLOWING CORONARY STENTING IN JAPANESE PATIENTS WITH AND WITHOUT 
PROTON PUMP INHIBITOR
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Ethnicity and its Effect on Lipids
Abstract Category: Pharmacology/Hormones/Lipids—Clinical
Presentation Number: 1074-99
Authors: Hideki Shimomura, Seiji Hokimoto, Hisao Ogawa, The KICS investigators, Fukuoka Tokusyukai Hospital, Kasuga, Japan, Kumamoto University, 
Kumamoto, Japan
Background: Concomitant use of clopidogrel and PPI is associated with the reduced effect on platelet response to clopidogrel, and increased risk 
of adverse outcome after stenting. The aim of this study was to examine the impact of PPI on clinical outcomes in Japanese patients with coronary 
artery disease (CAD). 
Methods: A total of 1,017 patients (male 712, 69 years) were enrolled and as dual antiplatelet therapy, aspirin and thienopyridine derivative 
were prescribed. Patients were divided into 2 groups; PPI and non-PPI. Moreover, adenosine diphosphate (ADP)-induced platelet aggregation was 
examined in 34 cases of 1,017 subjects on antiplatelet therapy. 
Results: PPI was prescribed in 260 cases (26%), and non-PPI in 757 (74%). As to cardiovascular event, there were no differences in mortality 
rate (PPI vs. non-PPI; 6 vs. 21 cases) and stent thrombosis (1 vs. 4) between PPI and non-PPI groups. There was also no difference in ADP-induced 
platelet aggregation between PPI and non-PPI (PPI vs. non-PPI; 4104±1485 vs. 3839±1620), although sample number measured of platelet 
aggregation was small.
Conclusion: Although the rate of clopidogrel use is different from that of Western countries, in contrast to the foreign reported negative drug 
interaction of PPI, the intake of PPI is not associated with increased risk of mortality and stent thrombosis in Japanese patients with CAD.
